My people, gather here make I yarn una wetin dey happen for our dear continent. Africa don land over 61,383 mpox cases and 296 deaths since early 2024, e no be small matter oh! Na the Africa Centres for Disease Control and Prevention talk am for statement wey dem release for Abuja.
Dem talk say plenty countries don join hand to develop better treatment options to tackle this mpox wahala. Na why Emergent BioSolutions don shake hands with the Pandemic Preparedness Platform to boost finance for the Africa CDC-led MpOx Study. This collaboration dey hot, e go help wey people wey dey affect by this mpox gist.
The MOSA initiative wey dem launch for 2024, na serious clinical trial wey dey check potential treatments for patients wey don catch mpox across different African countries. Director General of Africa CDC, Dr. Jean Kaseya, don drop sense talk say this study na big deal, e go help us respond to new and old public health threats. E talk say, “This study represent critical step in generating evidence to inform mpox treatment and strengthen Africa’s capacity to respond to emerging health threats.”
As e be now, Africa CDC dey work tight with partners to improve research, preparedness, and fast response if wahala show face again. They don also get independent Data and Safety Monitoring Board wey don finished their first review for safety data in December 2025. God dey with us, dem don recommend say this trial fit continue without any safety wahala.
Dr. Simon Lowry wey be Chief Medical Officer for Emergent BioSolutions don talk say dem dey proud to support this trial. “We dey hail Africa CDC and the investigators from Democratic Republic of Congo for their good work to reach this milestone. We go keep dey collaborate to face global health threats,” Lowry talk.
This study wey don get support from European Union and Africa CDC don focus mostly on DRC, one of the countries wey dey suffer from mpox matter. Now, Africa CDC and PANTHER go expand the trial to plenty countries like Uganda as dem dey enroll more patients.
Dem yak say Africa dey face two major mpox clades: Clade I wey dey common for Central Africa and dey cause more serious illness, and Clade II wey dey happen well well for West Africa. Recent outbreaks don also mix with subclades like Clade Ia, Ib, IIa and IIb. E mean say we get work to do to test better treatments since as e dey now, we no get any dedicated antiviral therapy for mpox.
Experts dey talk say the MOSA trial dey significant wella, e go help improve treatment options and strengthen preparedness for any pandemic matter wey fit show face for Africa again. Na wetin we go dey focus on so that we no go dey depend on anybody. Africa fit do am, we go show say we fit manage our health challenges.”
Do you have a news tip for NNN? Please email us at editor @ nnn.ng
